Cargando…

Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study

INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Younger, E., Jones, R.L., den Hollander, D., Soomers, V.L.M.N., Desar, I.M.E., Benson, C., Young, R.J., Oosten, A.W., de Haan, J.J., Miah, A., Zaidi, S., Gelderblom, H., Steeghs, N., Husson, O., van der Graaf, W.T.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441156/
https://www.ncbi.nlm.nih.gov/pubmed/34509803
http://dx.doi.org/10.1016/j.esmoop.2021.100258
_version_ 1783752818936512512
author Younger, E.
Jones, R.L.
den Hollander, D.
Soomers, V.L.M.N.
Desar, I.M.E.
Benson, C.
Young, R.J.
Oosten, A.W.
de Haan, J.J.
Miah, A.
Zaidi, S.
Gelderblom, H.
Steeghs, N.
Husson, O.
van der Graaf, W.T.A.
author_facet Younger, E.
Jones, R.L.
den Hollander, D.
Soomers, V.L.M.N.
Desar, I.M.E.
Benson, C.
Young, R.J.
Oosten, A.W.
de Haan, J.J.
Miah, A.
Zaidi, S.
Gelderblom, H.
Steeghs, N.
Husson, O.
van der Graaf, W.T.A.
author_sort Younger, E.
collection PubMed
description INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND METHODS: The prospective HOLISTIC study was conducted in the UK and the Netherlands assessing health-related quality of life in STS patients receiving palliative chemotherapy. Participants completed a questionnaire before starting chemotherapy, including attitudes towards quality of life (QoL) versus length of life (LoL), decisional control preferences, and decisional conflict. Chi-square and Fisher’s exact tests were used to evaluate associations between patient characteristics and preferences. RESULTS: One hundred and thirty-seven patients with advanced STS participated (UK: n = 72, the Netherlands: n = 65). Median age was 62 (27-79) years. Preference for extended LoL (n = 66, 48%) was slightly more common than preference for QoL (n = 56, 41%); 12 patients (9%) valued LoL and QoL equally (missing: n = 3). Younger patients (age <40 years) prioritised LoL, whereas two-thirds of older patients (aged ≥65 years) felt that QoL was equally or more important than LoL (P = 0.020). Decisional conflict was most common in patients who prioritised QoL (P = 0.024). Most patients preferred an active (n = 45, 33%) or collaborative (n = 59, 44%) role in treatment decisions. Gender, performance status, and country were significantly associated with preferred role. Concordance between preferred and actual role in chemotherapy decision was high (n = 104, 76%). CONCLUSIONS: Heterogeneous priorities and preferences among advanced STS patients support personalised decisions about palliative treatment. Considering individual differences during treatment discussions may enhance communication and optimise patient-centred care.
format Online
Article
Text
id pubmed-8441156
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84411562021-09-21 Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A. Zaidi, S. Gelderblom, H. Steeghs, N. Husson, O. van der Graaf, W.T.A. ESMO Open Original Research INTRODUCTION: Palliative chemotherapy is the principal treatment of patients with advanced soft tissue sarcomas (STS); however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and priorities are central to personalised treatment decisions. PATIENTS AND METHODS: The prospective HOLISTIC study was conducted in the UK and the Netherlands assessing health-related quality of life in STS patients receiving palliative chemotherapy. Participants completed a questionnaire before starting chemotherapy, including attitudes towards quality of life (QoL) versus length of life (LoL), decisional control preferences, and decisional conflict. Chi-square and Fisher’s exact tests were used to evaluate associations between patient characteristics and preferences. RESULTS: One hundred and thirty-seven patients with advanced STS participated (UK: n = 72, the Netherlands: n = 65). Median age was 62 (27-79) years. Preference for extended LoL (n = 66, 48%) was slightly more common than preference for QoL (n = 56, 41%); 12 patients (9%) valued LoL and QoL equally (missing: n = 3). Younger patients (age <40 years) prioritised LoL, whereas two-thirds of older patients (aged ≥65 years) felt that QoL was equally or more important than LoL (P = 0.020). Decisional conflict was most common in patients who prioritised QoL (P = 0.024). Most patients preferred an active (n = 45, 33%) or collaborative (n = 59, 44%) role in treatment decisions. Gender, performance status, and country were significantly associated with preferred role. Concordance between preferred and actual role in chemotherapy decision was high (n = 104, 76%). CONCLUSIONS: Heterogeneous priorities and preferences among advanced STS patients support personalised decisions about palliative treatment. Considering individual differences during treatment discussions may enhance communication and optimise patient-centred care. Elsevier 2021-09-09 /pmc/articles/PMC8441156/ /pubmed/34509803 http://dx.doi.org/10.1016/j.esmoop.2021.100258 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Younger, E.
Jones, R.L.
den Hollander, D.
Soomers, V.L.M.N.
Desar, I.M.E.
Benson, C.
Young, R.J.
Oosten, A.W.
de Haan, J.J.
Miah, A.
Zaidi, S.
Gelderblom, H.
Steeghs, N.
Husson, O.
van der Graaf, W.T.A.
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title_full Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title_fullStr Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title_full_unstemmed Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title_short Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
title_sort priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the holistic study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441156/
https://www.ncbi.nlm.nih.gov/pubmed/34509803
http://dx.doi.org/10.1016/j.esmoop.2021.100258
work_keys_str_mv AT youngere prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT jonesrl prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT denhollanderd prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT soomersvlmn prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT desarime prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT bensonc prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT youngrj prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT oostenaw prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT dehaanjj prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT miaha prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT zaidis prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT gelderblomh prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT steeghsn prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT hussono prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy
AT vandergraafwta prioritiesandpreferencesofadvancedsofttissuesarcomapatientsstartingpalliativechemotherapybaselineresultsfromtheholisticstudy